Coute Ryan A, Panchal Ashish R, Mader Timothy J, Neumar Robert W
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI
Kansas City University of Medicine and Biosciences, Kansas City, MO.
J Am Heart Assoc. 2017 Jul 12;6(7):e005239. doi: 10.1161/JAHA.116.005239.
Cardiac arrest (CA) is a leading cause of death in the United States, claiming over 450 000 lives annually. Improving survival depends on the ability to conduct CA research and on the translation and implementation of research findings into practice. Our objective was to provide a descriptive analysis of annual National Institutes of Health (NIH) funding for CA research over the past decade.
A search within NIH RePORTER for the years 2007 to 2016 was performed using the terms: "cardiac arrest" or "cardiopulmonary resuscitation" or "heart arrest" or "circulatory arrest" or "pulseless electrical activity" or "ventricular fibrillation" or "resuscitation." Grants were reviewed and categorized as CA research (yes/no) using predefined criteria. The annual NIH funding for CA research, number of individual grants, and principal investigators were tabulated. The total NIH investment in CA research for 2015 was calculated and compared to those for other leading causes of death within the United States. Interrater reliability among 3 independent reviewers for fiscal year 2015 was assessed using Fleiss κ. The search yielded 2763 NIH-funded grants, of which 745 (27.0%) were classified as CA research (κ=0.86 [95%CI 0.80-0.93]). Total inflation-adjusted NIH funding for CA research was $35.4 million in 2007, peaked at $76.7 million in 2010, and has decreased to $28.5 million in 2016. Per annual death, NIH invests ≈$2200 for stroke, ≈$2100 for heart disease, and ≈$91 for CA.
This analysis demonstrates that the annual NIH investment in CA research is low relative to other leading causes of death in the United States and has declined over the past decade.
心脏骤停（CA）是美国主要的死亡原因之一，每年导致超过45万人死亡。提高生存率取决于开展心脏骤停研究的能力以及将研究结果转化并应用于实践的能力。我们的目标是对美国国立卫生研究院（NIH）在过去十年中每年用于心脏骤停研究的资金进行描述性分析。
在NIH RePORTER中使用以下检索词对2007年至2016年的数据进行检索：“心脏骤停”或“心肺复苏”或“心跳骤停”或“循环骤停”或“无脉电活动”或“心室颤动”或“复苏”。根据预先设定的标准对拨款进行审查并归类为心脏骤停研究（是/否）。统计了NIH每年用于心脏骤停研究的资金、单个拨款的数量以及主要研究者的数量。计算了2015年NIH对心脏骤停研究的总投资，并与美国其他主要死亡原因的投资进行了比较。使用Fleiss κ评估了2015财年3名独立评审员之间的评分者间信度。检索共获得2763项由NIH资助的拨款，其中745项（27.0%）被归类为心脏骤停研究（κ=0.86[95%CI 0.80-0.93]）。经通胀调整后，NIH在2007年用于心脏骤停研究的资金为3540万美元，2010年达到峰值7670万美元，2016年降至2850万美元。NIH每年为中风死亡患者投资约2200美元，为心脏病死亡患者投资约2100美元，为心脏骤停死亡患者投资约91美元。
该分析表明，相对于美国其他主要死亡原因，NIH每年对心脏骤停研究的投资较低，且在过去十年中有所下降。
